Name : Cynomolgus IL-1 Rrp2/IL-1 R6 Protein
Product Source :
Recombinant Cynomolgus IL-1 Rrp2/IL-1 R6 Protein is expressed from HEK293 with His tag at the C-Terminus. It contains Asp20-Arg335.[Accession | EHH61702.1]
Molecular Weight :
The protein has a predicted MW of 37.1 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Cynomolgus IL-1 Rrp2/IL-1 R6 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Cynomolgus IL-1 Rrp2/IL-1 R6 is greater than 95% as determined by SEC-HPLC.
Background :
The Interleukin 1 receptor family (IL-1 R) comprises at least eleven members including IL-1 RI (IL-1 R1), IL-1 RII (IL-1 R2), IL-1 RAcP (IL‑1 R3), ST2 (T1/IL-1 R4), IL-18 Ra (IL-1 Rrp/IL-1 R5), IL-1 Rrp2 (IL-1 RL2/IL-1 R6), IL-18 Rb (AcPL/IL-1 R7), IL-1RAPL‑1 (TIGIRR‑2/IL‑1 R8), and TIGIRR-1 (IL-1 R9). IL1RL2 is a receptor for interleukin-36 (IL36A, IL36B and IL36G). After binding to interleukin-36 associates with the coreceptor IL1RAP to form the interleukin-36 receptor complex which mediates interleukin-36-dependent activation of NF-kappa-B, MAPK and other pathways.
Synonyms :
IL-1 R6; IL-1 Rrp2; IL1RL2; IL1Rrp2; IL1RRP2; IL-36R
References & Citations :
(1)Mahil S K , Catapano M , Di Meglio P , et al. An analysis of IL-36 signature genes and individuals with\r, IL1RL2\r, knockout mutations validates IL-36 as a psoriasis therapeutic target[J]. Science Translational Medicine, 2017, 9(411):eaan2514.D
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
TPM4 Protein
CD40 Protein
Popular categories:
Thyroid Hormone Receptor
Complement Component 8 gamma Chain